Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women.

@article{Carvalho2010SustainedEA,
  title={Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women.},
  author={Nat{\'a}lia Cassettari de Carvalho and Jacobsen Teixeira and Cecilia Maria Roteli-Martins and Pierre Naud and P Colares de Borba and Toufik Zahaf and Norman S{\`a}nchez and Anne E Schuind},
  journal={Vaccine},
  year={2010},
  volume={28 38},
  pages={6247-55}
}
We report efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years post-vaccination. The study was conducted in a population (N=433) of women enrolled in Brazilian centres from an initial placebo-controlled study. Women were aged 15-25 years at first vaccination. During the most recent year of follow-up, approximately 7 years after initial vaccination, no cases of infection or cytohistological lesions associated with HPV-16/18 were observed in the vaccinees. Vaccine… CONTINUE READING

From This Paper

Topics from this paper.
64 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 64 extracted citations

Similar Papers

Loading similar papers…